Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
Public ClinicalTrials.gov record NCT00677365. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP-376 Solution for Inhalation Given for 28 Days to Stable CF Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. Bacterial resistance to current aerosol antibiotic treatments indicate a need for improved therapies to treat CF patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to have antimicrobial effects on even the most resistant organisms.
Study identification
- NCT ID
- NCT00677365
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 151 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2008 (Type not available)
- Primary completion
- Jun 2009 (Actual)
- Completion
- Jun 2009 (Actual)
- Last update posted
- Dec 27, 2024
2008 – 2009
United States locations
- U.S. sites
- 39
- U.S. states
- 21
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Mobile | Alabama | 36608 | — |
| Not listed | Phoenix | Arizona | 85016 | — |
| Not listed | Tucson | Arizona | 85724 | — |
| Not listed | Little Rock | Arkansas | 72202 | — |
| Childrens Hospital | Los Angeles | California | 90027 | — |
| Not listed | Los Angeles | California | 90033 | — |
| Not listed | Oakland | California | 94611 | — |
| Not listed | Orange | California | 92868 | — |
| Not listed | Palo Alto | California | 94304 | — |
| Not listed | Sacramento | California | 95817 | — |
| Not listed | San Diego | California | 92103 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Orlando | Florida | 32801 | — |
| Not listed | Chicago | Illinois | 60025 | — |
| Not listed | Oak Lawn | Illinois | 60453 | — |
| Not listed | Park Ridge | Illinois | 60068 | — |
| Not listed | Iowa City | Iowa | 52242 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | Boston | Massachusetts | 02115 | — |
| Not listed | Ann Arbor | Michigan | 48109 | — |
| Not listed | Kalamazoo | Michigan | 49007 | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | Las Vegas | Nevada | 89107 | — |
| Not listed | Morristown | New Jersey | 07962 | — |
| Not listed | Albany | New York | 12208 | — |
| Not listed | Valhalla | New York | 10595 | — |
| Not listed | Cincinnati | Ohio | 45224 | — |
| Not listed | Columbus | Ohio | 43205 | — |
| Not listed | Dayton | Ohio | 45404 | — |
| Oklahoma CF Center | Oklahoma City | Oklahoma | 73104 | — |
| Not listed | Oklahoma City | Oklahoma | 73112 | — |
| Not listed | Philadelphia | Pennsylvania | 19102 | — |
| Not listed | Pittsburgh | Pennsylvania | 15213 | — |
| Not listed | Charleston | South Carolina | 29425 | — |
| Not listed | Columbia | South Carolina | 29203 | — |
| Not listed | Memphis | Tennessee | 38105 | — |
| Not listed | San Antonio | Texas | 78212 | — |
| Not listed | Tyler | Texas | 75708 | — |
| Not listed | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00677365, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 27, 2024 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00677365 live on ClinicalTrials.gov.